REFERENCIAS
- Hirsh
J, Dalen JE, Anderson D, et al. Oral Anticoagulants. Mechanism of
action, clinical effectiveness and optimal therapeutic range. Chest
1998; 114 Suppl: 445S-469S.
- Walker
ID, Machin S, Baglin TP, et al. Guidelines on oral anticoagulation.
3rd ed. Br J Haematol 1998; 101: 374-387.
- Holbrook
AM, Wells PS, Crowther NR. Pharmacokinetics and drug interactions
with warfarin. In: Poller L, Hirsh J, editors. Oral anticoagulants.
Sydney: Arnold, 1996: 30-48.
- Crowther
MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5 mg
and 10 mg warfarin loading doses. Arch Intern Med 1999;
159: 46-48.
- Rose
P. Audit of anticoagulant therapy. J Clin Pathol 1996;
49: 5-9.
- Coumadin
and Marevan are not interchangeable. Aust Adverse Drug React
(ADRAC) Bull 1999; 18:6.
- van
der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications
in oral anticoagulant therapy: an analysis of risk factors.
Arch Intern Med 1993; 153: 1557-1562.
- Cannegieter
SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy
in patients with mechanical heart valves. N Engl J Med
1995; 333: 11-17.
- Levine
M, Raskob GE, Landefeld S, Kearon C. Hemorrhagic complications of
anticoagulant treatment. Chest 1998; 114 Suppl:
511S-523S.
- Laupacis
A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy
of antithrombotic therapy in atrial fibrillation. Analysis of pooled
data from five randomized controlled trials. Arch Intern Med
1994; 154: 1449-1457.
- The
European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant
therapy in patients with nonrheumatic atrial fibrillation and recent
cerebral ischemia. N Engl J Med 1995; 333: 5-10.
- The
Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
A randomized trial of anticoagulants versus aspirin after cerebral
ischemia of presumed arterial origin. Ann Neurol 1997;
42: 857-865.
- Landefeld
S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology,
prediction and prevention. Am J Med 1993; 95:
315-328.
- Fihn
SD, McDonnell M, Martin D, et al. Risk factors for complications of
chronic anticoagulation. A multicenter study. Ann Intern Med
1993; 118: 511-520.
- Palareti
G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant
treatment: an inception-cohort, prospective collaborative study (ISCOAT).
Lancet 1996; 348: 423-428.
- Hylek
EM, Singer D. Risk factors for intracranial hemorrhage in outpatients
taking warfarin. Ann Intern Med 1994; 120: 897-902.
- Weibert
RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation
with low-dose oral vitamin K1. Ann Intern Med 1997;
125: 959-962.
- Crowther
M, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably
reverses over-anticoagulation due to warfarin. Thromb Haemost
1998; 79: 1116-1118.
- Makris
M, Greaves M, Philips W, et al. Emergency oral anticoagulant reversal:
the relative efficacy of infusions of fresh frozen plasma and clotting
factor concentrate on correction of the coagulopathy. Thromb
Haemost 1996; 77: 477-480.
- Kearon
C, Hirsh J. Management of anticoagulation before and after elective
surgery. N Engl J Med 1997; 336: 1506-1511.
- Clagett
GP, Anderson FA, Geerts WH, et al. Prevention of venous thromboembolism.
Chest 1998; 114 Suppl: 531S-560S.
- Hyers
TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic
disease. Chest 1998; 114 Suppl: 561S-578S.
- Koopman
MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis
with intravenous unfractionated heparin administered in the hospital
as compared with subcutaneous low-molecular-weight heparin administered
at home. N Engl J Med 1996; 334: 682-687.
- Levine
M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin
administered primarily at home with unfractionated heparin administered
in the hospital for proximal deep-vein thrombosis. N Engl J
Med 1996; 334: 677-681.
- Schulman
S, Rhedin A-S, Lindmarker P, et al. Comparison of six weeks with six
months of oral anticoagulant therapy after a first episode of venous
thromboembolism. N Engl J Med 1995; 332: 1661-1665.
- Levine
MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant
therapy: a randomized trial comparing four weeks with three months
of warfarin in patients with proximal DVT. Thromb Haemost
1995; 74: 606-611.
- Schulman
S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant
therapy after a second episode of venous thromboembolism. N
Engl J Med 1997; 336: 393-398.
- van
den Belt AGM, Sanson B-J, Simioni P, et al. Recurrence of venous thromboembolism
in patients with familial thrombophilia. Arch Intern Med
1997; 157: 2227-2232.
- Simioni
P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism
in patients with an Arg506 to Gln mutation in the gene for factor
V (Factor V Leiden).
N Engl J Med 1997; 336: 399-403.
- Kearon
C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation
with extended anticoagulation for a first episode of idiopathic venous
thromboembolism. N Engl J Med 1999; 340: 901-907.
- Lagerstedt
CI, Olsson C-G, Fagher BO, et al. Need for long-term anticoagulant
treatment in symptomatic calf-vein thrombosis. Lancet 1985;
2: 515-518.
- Wells
PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest
probability of deep-vein thrombosis in clinical management.
Lancet 1997; 350: 1795-1798.
- Heijboer
H, Buller HR, Lensing AW, et al. A comparison of real-time compression
ultrasonography with impedance plethysmography for the diagnosis of
deep-vein thrombosis in symptomatic outpatients. N Engl J Med
1993; 329: 1365-1369.
- Singer
DE. Overview of the randomized trials to prevent stroke in atrial
fibrillation. Ann Epidemiol 1993; 3: 563-567.
- Laupacis
A, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation.
Chest 1998; 114 Suppl: 579S-589S.
- Hylek
EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective
intensity of prophylactic anticoagulation for patients with nonrheumatic
atrial fibrillation. N Engl J Med 1996; 335:
540-546.
- Stroke
Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin
versus low-intensity, fixed-dose warfarin plus aspirin for high-risk
patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation
III randomised clinical trial. Lancet 1996; 348:
633-638.
- Miller
VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin
versus warfarin on clinical stroke types in patients with atrial fibrillation.
Neurology 1996; 46: 238-240.
- European
Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic
atrial fibrillation after transient ischaemic attack or minor stroke.
Lancet 1993; 342: 1255-1262.
- Cairns
JA, Theroux P, Lewis HD Jr, et al. Antithrombotic agents in coronary
artery disease. Chest 1998; 114 Suppl: 611S-633S.
- Fuster
V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic
dilated cardiomyopathy. Am J Cardiol 1981; 47:
525-531.
- Al-Khadra
AS, Salem DN, Rabd WR, et al. Warfarin anticoagulation and survival:
a cohort analysis from the studies of left ventricular dysfunction.
J Am Coll Cardiol 1998; 31: 749-753.
- Stein
PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in patients
with mechanical and biological prosthetic heart valves. Chest
1998; 114 Suppl: 602S-610S.
- Cappelleri
JC, Fiore LD, Brophy MT, et al. Efficacy and safety of combined anticoagulant
and antiplatelet therapy versus anticoagulant monotherapy after mechanical
heart-valve replacement: a metaanalysis. Am Heart J 1995;
130: 547-552.
- Rosove
MH, Brewer PM. Antiphospholipid thrombosis: clinical course after
the first thrombotic event in 70 patients. Ann Intern Med
1992; 117: 303-308.
- Khamashta
MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the
antiphospholipid-antibody syndrome. N Engl J Med 1995;
332: 993-997.
- Krnic-Barrie
S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients
with antiphospholipid syndrome: analysis of factors influencing recurrent
thrombosis. Arch Intern Med 1997; 157: 2101-2108.
- Eichinger
S, Pabinger I, Stumpflen, et al. The risk of recurrent venous thromboembolism
in patients with and without Factor V Leiden. Thromb Haemost
1997; 77: 624-628.
-
Ginsberg J, Barron W. Pregnancy and prosthetic heart valves. Lancet
1994; 344: 1170-1172.
- Koren
G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med
1998; 338: 1128-1137.
- Hall
JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation
during pregnancy. Am J Med 1980; 68: 122-140.
- Iturbe-Alessio
I, del Carmen Fonseca M, Mutchinik O, et al. Risks of anticoagulant
therapy in pregnant women with artificial heart valves. N Engl
J Med 1986; 315: 1390-1393.
- Ginsberg
JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy.
Risks to the fetus and mother. Arch Intern Med 1989;
149: 2233-2236.
- Fejgin
MD, Lourwood DL. Low molecular weight heparins and their use in obstetrics
and gynecology. Obstet Gynecol Surv 1994; 49:
424-431.
- Sanson
B-J, Lensing AWA, Prins MH, et al. Safety of low-molecular-weight
heparin in pregnancy: a systematic review. Thromb Haemost 1999;
81: 668-672.
- Orme
ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed
their infants? BMJ 1977; 1: 1564-1565.
|